cas 84348-37-8, N-Boc-4-oxo-L-proline | Articles data

Articles about 84348-37-8Total 36 be found

Article title
Article abstract
Author
Journal number and time
Download

Altering the sex pheromone cyclo(L-pro-l-pro) of the diatom seminavis robusta towards a chemical probe
As a major group of algae, diatoms are responsible for a substantial part of the primary production on the planet. Pennate diatoms have a predominantly benthic lifestyle and are the most species-rich diatom group, with members of the raphid clades being motile and generally having heterothallic sexual reproduction. It was recently shown that the model species Seminavis robusta uses multiple sexual cues during mating, including cyclo(L-Pro-L-Pro) as an attraction pheromone. Elaboration of the pheromone-detection system is a key aspect in elucidating pennate diatom life-cycle regulation that could yield novel fundamental insights into diatom speciation. This study reports the synthesis and bio-evaluation of seven novel pheromone analogs containing small structural alterations to the cyclo(L-Pro-L-Pro) pheromone. Toxicity, attraction, and interference assays were applied to assess their potential activity as a pheromone. Most of our analogs show a moderate-to-good bioactivity and low-to-no phytotoxicity. The pheromone activity of azide-and diazirine-containing analogs was unaffected and induced a similar mating behavior as the natural pheromone. These results demonstrate that the introduction of confined structural modifications can be used to develop a chemical probe based on the diazirine-and/or azide-containing analogs to study the pheromone-detection system of S. robusta.
Bonneure, Eli,De Baets, Amber,De Decker, Sam,Van den Berge, Koen,Clement, Lieven,Vyverman, Wim,Mangelinckx, Sven
p. 1 - 14
(2021/01/26)

Method for synthesizing tert-2-(3- (2S)-4- butyl)-1- ester of n-oxo-isothiazole alkyloxycarbonylpyrrolidinecarboxylic acid (by machine translation)
The technical scheme of the present (2S) - 4 - invention is that the following) - 1 - technical scheme of the present invention, is that the compound is obtained. by the continuous production of the: compound having L - the following beneficial, effects: the Boc compound is obtained II, from the following technical scheme III, No.No. STR3, No.No. IV; The technical proposal of the present invention is the following technical proposal: II No.No. STR3 III. No., No. The following technical II, proposal III Boc - L - of the present, N - Boc - 4 - IV invention is the following (2S) - 4 -) - 1 - technical proposal: No.No. STR8. No. II No.No. :(1) STR8 III, No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR2, No.No.No. STR8No.No.No.No. .(2) STR8No., No.No.No.. STR8No., No.No.No., STR2No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR8No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR8No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR7No.No.No.No. STR2No.No.No. STR7No.No.No.No. ST (by machine translation)
-
Paragraph 0038; 0041-0042; 0053; 0056-0057; 0066; 0069-0070

(2020/02/14)

Synthesis of 4-(Arylmethyl)proline Derivatives
A synthesis of 4 - (arylmethyl)proline by using Suzuki cross-couplings was developed. The route permits access to a variety of 4-substituted proline derivatives bearing various aryl moieties that expand the toolbox of proline analogues for studies in chemistry and biology.
Loosli, Simon,Foletti, Carlotta,Papmeyer, Marcus,Wennemers, Helma
supporting information
p. 508 - 510
(2019/02/26)

Industrial production method of teneligptin intermediate
The invention relates to the technical field of biochemical engineering, in particular to an industrial production method of a teneligptin intermediate (2S)-4-oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester. The method comprises the following steps: oxidizing a raw material N-Boc-hydroxyproline through an oxidizing agent in the presence of a catalyst; performing quenching with water after reaction ends, singly treating water phase in a waste water treatment pipeline, and concentrating organic phase, so as to obtain a product N-Boc-4-oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester crude product, and performing recrystallization on the crude product through a solvent, so as to obtain a finished product. Compared with the prior art,the industrial production method has the advantages that high-quality (2S)-4-oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester can be efficiently and stably produced, the purity is greater than 99 percent, unknown single impurity is smaller than 0.3 percent, and three-waste treatment reach the standards.
-
Paragraph 0023-0028; 0034-0039; 0045-0050; 0056-0061

(2019/04/04)

Ledipasvir preparation method
The invention discloses a Ledipasvir preparation method. The Ledipasvir preparation method includes steps: (1) Ledipasvir intermediate product 1-LD-B preparation; (2) Ledipasvir intermediate product 2-LD-E preparation; (3) Ledipasvir intermediate product 3-LD-F preparation; (4) Ledipasvir intermediate product 4-LD-J preparation; (5) Ledipasvir intermediate product 5-LD-L preparation; (6) Ledipasvir-LD-Q preparation. The Ledipasvir preparation method has advantages of technical maturity and stability, product quality stability, safety and reliability in production process and suitableness for industrial production.
-
Paragraph 0075; 0077; 0078; 0148; 0217

(2018/05/16)

Synthesis technology of N-Boc-4-oxo-L-proline tert-butyl ester
The invention discloses a synthesis technology of N-Boc-4-oxo-L-proline tert-butyl ester, and relates to the technical field of medicine synthesis. The synthesis technology solves the problems that inthe prior art, the production cost is low, the product yield is low, and the synthesis technology is not suitable for industrial production. According to the synthesis technology, Boc anhydride is used to generate tert-butyl carbonate, special esterification reagents namely O-tert-butyl-N,N'-diisopropyl isourea and EDC condensation reagent are not used, and the production cost is reduced by morethan 70%. Sodium hypochlorite is directly used to replace ruthenium tetroxide and chromium trioxide to prepare oxidized hydroxyl and is safe and reliable, furthermore, the post treatment is simple, the environmental pollution is greatly reduced, the operation of the synthesis technology is easy to perform, the technological conditions are easy to control, the synthesis technology is suitable for massive production, and the yield of step three can reach 69% and is higher than that of a conventional technology.
-
Paragraph 0018

(2018/07/30)

Preparation method of N-t-butyloxycarboryl-ketone-L-proline
The invention relates to a preparation method of N-t-butyloxycarboryl-ketone-L-proline, and belongs to the technical field of synthesis of drug intermediates. In order to solve the problems that existing reaction is dramatic and low in safety and the product yield stability is low, the invention provides the preparation method of the N-t-butyloxycarboryl-ketone-L-proline. The method comprises thefollowing steps: under the existence of an inorganic alkaline reagent, enabling L-hydroxyproline to react with di-tert-butyl dicarbonate ester in a mixed solvent of water and a water-soluble organic solvent, and removing the organic solvent at the end of the reaction, thereby obtaining a residual aqueous solution containing an intermediate product carboxylate; and under the existence of a TEMPO catalyst, directly generating oxidizing reaction between the obtained intermediate product carboxylate and dihalide isocyanurate, and acidifying a product at the end of the reaction, thus obtaining theproduct N-t-butyloxycarboryl-ketone-L-proline. The preparation method can realize stable reaction, so as to achieve effects of increasing the yield and improving the purity.
-
Paragraph 0025; 0028; 0031; 0034; 0035; 0037; 0041;

(2018/09/12)

Synthesis of 4 - oxo - L - proline derivatives (by machine translation)
The invention relates to the field of preparation methods of chemical drug intermediates, in particular to a method for synthesizing a 4-oxo-L-proline derivative. The method comprises steps as follows: L-hydroxyproline and an oxidant are mixed, and a mixture is obtained and reacts to produce an intermediate product; after an amino-group protective agent is added to a solution containing the intermediate product, the mixture reacts continuously; then, the mixture has a quenching reaction and is subjected to acidification, extraction, separation, drying and purification, and the 4-oxo-L-proline derivative is obtained. According to the method for synthesizing the 4-oxo-L-proline derivative, the primary raw material L-hydroxyproline is low in cost and easy to obtain; the whole synthesizing steps are convenient, simple and easy to operate; poisonous reagents such as heavy metals and the like are not used in the production process, and the 4-oxo-L-proline derivative is environment-friendly, low in cost and suitable for industrial production.
-
Paragraph 0062; 0065; 0066; 0067; 0068; 0069; 0070; 0071

(2018/11/03)

Method for preparing hydrobromic acid teneligliptin
The invention provides a method for preparing hydrobromic acid teneligliptin. The method includes steps of preparing L-hydroxyproline; mixing the L-hydroxyproline and sodium bicarbonate with each other to obtain mixtures, dissolving the mixtures in water, adding acetone into the water, dropping di-tert-butyl dicarbonate into the water, carrying out room-temperature reaction overnight and then treating reaction products to obtain t-butyloxycarboryl-N-hydroxyproline; preparing t-butyloxycarboryl-N-4-oxo-proline from the t-butyloxycarboryl-N-hydroxyproline; preparing (2S)-4-oxo-2-(3-thiazolidine carbonyl)-1-pyrrolidine carboxylic acid tert-butyl ester from the t-butyloxycarboryl-N-4-oxo-proline; preparing compounds III from compounds IV; preparing compounds II from the compounds III; preparing compounds 1-(3-methyl-1-phenyl-1H-pyrazole-5-base) piperazine from the compounds II; preparing intermediates I; preparing the hydrobromic acid teneligliptin from the intermediates I. The method has the advantages that the method is low in cost, and the cost of the method is only two-thirds of the cost of an existing method in the prior art; the yield of the hydrobromic acid teneligliptin is higher than 95%, and the purity of the hydrobromic acid teneligliptin is higher than 98%.
-
Paragraph 0043; 0044; 0051

(2017/07/01)

Chemical Probes Unravel an Antimicrobial Defense Response Triggered by Binding of the Human Opioid Dynorphin to a Bacterial Sensor Kinase
Host-microbe communication via small molecule signals is important for both symbiotic and pathogenic relationships, but is often poorly understood at the molecular level. Under conditions of host stress, levels of the human opioid peptide dynorphin are elevated, triggering virulence in the opportunistic pathogenic bacterium Pseudomonas aeruginosa via an unknown pathway. Here we apply a multilayered chemical biology strategy to unravel the mode of action of this putative interkingdom signal. We designed and applied dynorphin-inspired photoaffinity probes to reveal the protein targets of the peptide in live bacteria via chemical proteomics. ParS, a largely uncharacterized membrane sensor of a two-component system, was identified as the most promising hit. Subsequent full proteome studies revealed that dynorphin(1-13) induces an antimicrobial peptide-like response in Pseudomonas, with specific upregulation of membrane defense mechanisms. No such response was observed in a parS mutant, which was more susceptible to dynorphin-induced toxicity. Thus, P. aeruginosa exploits the ParS sensing machinery to defend itself against the host in response to dynorphin as a signal. This study highlights interkingdom communication as a potential essential strategy not only for induction of P. aeruginosa virulence but also for maintaining viability in the hostile environment of the host.
Wright, Megan H.,Fetzer, Christian,Sieber, Stephan A.
supporting information
p. 6152 - 6159
(2017/05/09)

Preparation method for medical intermediate N-Boc-cis-4-hydroxy-L-proline
The invention provides a preparation method for a medical intermediate N-Boc-cis-4-hydroxy-L-proline. The preparation method comprises the following steps: with L-hydroxyproline as a raw material, subjecting the raw material to Boc protection; then carrying out hydroxyl radical oxidation so as to obtain N-Boc-4-oxo-L-proline; dissolving N-Boc-4-oxo-L-proline in a solvent and successively carrying out reduction with a reducing agent and purification at a certain temperature so as to obtain the product N-Boc-cis-4-hydroxy-L-proline. The method has the advantages of good reaction selectivity, high product ee value and low preparation cost.
-
Paragraph 0019-0020

(2017/04/26)

SYNTHETIC SPHINGOLIPID-LIKE MOLECULES, DRUGS, METHODS OF THEIR SYNTHESIS AND METHODS OF TREATMENT
Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, canc
-
Paragraph 00149

(2017/04/11)

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
-
Paragraph 0758

(2017/03/14)

PROCESS FOR THE SYNTHESIS OF PROTECTED 4-KETO-PROLINE
Disclosed is a process for the synthesis of N-protected 4-keto-prolines (1), starting with the corresponding protected 4-hydroxyproline, in the presence of the oxidising system P2O5/dimethylsulphoxide (DMSO). Said process can also be applied in the presence of a chiral centre in the position bearing carboxylic acid (the 3 position) without significant epimerisation of said centre. Said process is particularly advantageous from the environmental standpoint and in terms of yields, productivity and the purity of the product obtained, since it does not use chromium-based oxidants, metals such as ruthenium, or oxidising systems which are precursors of genotoxic impurities.
-
Page/Page column 6

(2017/03/08)

(4S)-N-Boc-4-methoxymethyl-L-proline synthesis method
The invention discloses a (4S)-N-Boc-4-methoxymethyl-L-proline synthesis method. The method comprises that 1, L-hydroxyproline as an initial raw material is subjected to Boc protection so that N-Boc-L-hydroxyproline is produced, 2, the N-Boc-L-hydroxyproline is dissolved in a solvent, the solution and 2, 2, 6, 6-tetramethyl-1-piperidinyloxy (TEMPO) undergo an oxidation reaction to produce (2S)-N-Boc-4-oxopyrrolidine-2-carboxylic acid, 3, the (2S)-N-Boc-4-oxopyrrolidine-2-carboxylic acid and (methoxymethyl)triphenylphosphonium chloride are dissolved in a solvent and undergo a wittig reaction to produce (2S)-N-Boc-4-methoxymethylenepyrrolidine-2-carboxylic acid, and 4, the (2S)-N-Boc-4-methoxymethylenepyrrolidine-2-carboxylic acid and tert-butylamine are dissolved in water and undergo a hydrogenation reaction to produce (4S)-N-Boc-4-methoxymethyl-L-proline. The method shortens reaction processes, is free of severe-toxicity cyanides, improves safety, reduces environmental protection pressure, improves atom economy, reduces waste discharge and greatly reduces a raw material cost.
-
Paragraph 0052; 0053

(2016/10/31)

PROCESS FOR THE PREPARATION OF (4R)-1-(TERT-BUTOXYCARBONYL)-4-HYDROXY-L-PROLINE
The present invention provides a process for the preparation of (4R)-1-(tert- butoxycarbonyl)-4-hydroxy-L-proline of Formula IV. The present invention also provides a process for the preparation of {(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-1-yl] pyrrolidin-2-yl}(1,3-thiazolidin-3-yl) methanone of Formula II, or salts thereof, using (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-L-proline of Formula IV.
-
Page/Page column 11 ; 12

(2016/06/20)

PROCESS FOR THE PREPARATION OF N-PROTECTED (5S)-5-(1,3-THIAZOLIDIN-3-YLCARBONYL)PYRROLIDIN-3-ONE
The present invention provides a process for the preparation of an N-protected (55)-5-(l,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one of Formula III. The invention also provides a process for the preparation of {(25',45)-4-[4-(3-methyl-l-phenyl-lH-pyrazol-5- yl)piperazin-l-yl]pyrrolidin-2-yl}(l,3-thiazolidin-3-yl)methanone, or salts thereof, using the N-protected (55)-5-(l,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one of Formula III. (III)
-
Page/Page column 9

(2015/02/25)

Development of a manufacturing process for an HCV protease inhibitor candidate molecule
The scale-up of a prototype HCV protease inhibitor (1) from gram scale in the laboratory to kilogram scale in the pilot plant is described. Key features of the optimization included the synthesis of bulk quantities of exomethylene proline intermediate 6, separation of the diastereomers of spirocycle 2 without chromatography, isolation of the precursor to 1 to purge byproducts that might raise genotoxic structural alerts, and purification of an amorphous drug substance via a crystalline acetic acid solvate.
Littler, Benjamin J.,Aizenberg, Michael,Ambhaikar, Narendra B.,Blythe, Todd A.,Curran, Timothy T.,Dvornikovs, Vadims,Jung, Young C.,Jurkauskas, Valdas,Lee, Elaine C.,Looker, Adam R.,Luong, Hoa,Martinot, Theodore A.,Miller, David B.,Neubert-Langille, Bobbianna J.,Otten, Pieter A.,Rose, Peter J.,Ruggiero, Piero L.
p. 270 - 283
(2015/01/30)

PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (la), (lb) and (Ic):
-
Page/Page column 18-19

(2012/12/13)

Synthesis and application of photoproline-a photoactivatable derivative of proline
A convenient synthesis is described of a derivative of L-proline called photoproline, containing a diazirine group at position-4 of the pyrrolidine ring, starting from L-4-hydroxyproline. The use of Fmoc-L-photoproline in the synthesis of a cyclic peptidomimetic antibiotic demonstrates that this photoprobe can be incorporated into synthetic peptides using solid-phase Fmoc chemistry. Photoproline may be of wide value in the preparation of diverse peptide-based photoaffinity probes. RKAT-USA, Inc.
Van Der Meijden, Benjamin,Robinson, John A.
experimental part
p. 130 - 136
(2011/06/17)

Inhibitors of Serine Proteases
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
-
(2010/12/26)

PYRROLOBENZODIAZEPINES
The invention relates to certain pyrrolobenzodiazepines (PBDs), and in particular pyrrolobenzodiazepine dimers bearing C2 substitutions, including compounds of formula (T): wherein: R2 is CHR2A, and R2A is independently selected from H, R, CO2R, COR, CHO, CO2H, and halo; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; R8 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; R is independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; or the compound is a dimer with each monomer being of formula (M), where the R7 groups or R8 groups of each monomer form together a dimer bridge having the formula -X-R"-X- linking the monomers; wherein R" is a C3-I2 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), and/or aromatic rings, e.g. benzene or pyridine; and each X is independently selected from O, S, or N(H); or any pair of adjacent groups from R6 to R9 together form a group -O-(CH2)P-O-, where p is 1 or 2, and salts and solvates thereof, and their use as intermediates for the preparation of other PBD compounds.
-
Page/Page column 51

(2010/04/30)

Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on Met residue replacement by 4-amino-proline scaffold: Synthesis and bioactivity
cis-(2S,4S) 4-Amino-proline (cAmp) and trans-(2S,4R) 4-amino-proline (tAmp) residues, bearing N-For or N-Boc substituents at the two amino groups, have been incorporated into the potent chemotactic agent fMLF-OMe in place of the N-terminal native (S)-methionine to give the analogues 17a-19a and 17b-19b. The new ligands have been examined for their activity (chemotaxis, superoxide anion production and lysozyme release) on human neutrophils as agonists and antagonists. Compounds 19a and 19b, bearing two N-For groups at the proline scaffold, are active and selective chemoattractants. The ligand 18b, containing N-For at the 4-amino group of the N-Boc-tAmp residue, exhibits significant chemotactic antagonism. The influence of the different substitution at the N-terminal position of the new analogues is discussed.
Torino, Domenica,Mollica, Adriano,Pinnen, Francesco,Feliciani, Federica,Spisani, Susanna,Lucente, Gino
experimental part
p. 251 - 259
(2011/03/19)

INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
-
Page/Page column 478

(2008/12/07)

INHIBITORS OF SERINE PROTEASES
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
-
Page/Page column 308-309

(2010/11/26)

Chemotactic peptides: fMLF-OMe analogues incorporating proline-methionine chimeras as N-terminal residue
The new fMLF analogues 1-4, incorporating chimeric S-proline-methionine residues (namely the homochiral cis-4(S)-methylthio-(S)-proline (10) and the heterochiral trans-4(R)-methylthio-(S)-proline) (17) in place of the native S-methionine, have been prepared; their solution conformation and activity as agonists or antagonists of formylpeptide receptors have been studied. In addition to peptides 1-4, which maintain the Met γ-thiomethyl-ether function, the analogues Boc-PLF-OMe (18) and For-PLF-OMe (19) devoid, as compared with 1-4, of position 1 side chain, have been synthesized and their activity examined.
Mollica, Adriano,Paradisi, Mario Paglialunga,Varani, Katia,Spisani, Susanna,Lucente, Gino
p. 2253 - 2265
(2007/10/03)

NITROGEN-CONTAINING COMPOUNDS
A compound represented by formula (I); wherein ring A represents a nitrogen containing heterocyclic ring, ring B represents 5-membered heterocyclic ring which may have substituents, R represents a hydrogen atom or cyano and the other symbols represent as
-
Page/Page column 39

(2010/02/11)

PROCESS FOR PREPARING N-PROTECTED 4-KETOPROLINE DERIVATIVES
The present invention is concerned with a process for preparing compounds of the general formula (I). These compounds can preferably be used to prepare bioactive agents. The reaction of the invention starts from the corresponding hydroxy compounds which are oxidized, with Ru catalysis, in a one-phase aqueous system.
-
Page/Page column 11-12

(2008/06/13)

PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS
The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1-C6-alkyl, for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea.
-
Page 30-31

(2008/06/13)

Pharmaceutically active pyrrolidine derivatives as bax inhibitors
The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CRR, NOR, NNRR; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NRR or represents a heterocyclic residue having the formula (II) wherein Q is NR, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.
-
(2008/06/13)

Pharmaceutically active pyrrolidine derivatives
The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.
-
(2008/06/13)

N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
-
(2008/06/13)

Synthesis of 4-cis-Phenyl-l-proline via Hydrogenolysis
-
Tamaki,Han,Hruby
p. 3593 - 3596
(2007/10/03)

Synthesis of kainoid analogues
4-oxoproline has been used as a chiral template in a synthesis of kainoid analogues which are epimeric with the parent compound at C-3.
Barraclough, Paul,Hudhomme, Pietrick,Spray, Caroline A.,Young, Douglas W.
p. 4195 - 4212
(2007/10/02)

Proline 4-hydroxylase: Stereochemical course of the reaction
The stereochemical course of the hydroxylation of (S)-proline by proline 4-hydroxylase from Streptomyces griseoviridus P8648 has been investigated using (2S, 4S)[4-2H1]-proline and (2S, 4R)-[4-2H1]-proline and found to occur with retention of stereochemistry at C-4 of proline.
Baldwin, Jack E.,Field, Robert A.,Lawrence, Christopher C.,Merritt, Kirsten D.,Schofield, Christopher J.
p. 7489 - 7492
(2007/10/02)